Phase 2 Parkinson's Disease Trial, Recruiting NCT07182058 Sponsor: U: The Mind Company Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 2 Parkinson's Disease Trial, Recruiting

NCT07182058
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 80 years old who have been officially diagnosed with Parkinson's Disease
  • People whose Parkinson's symptoms fall within a certain range of severity (from mild to moderately severe — confirm with trial site what this means for you)
  • People who have been on a stable, unchanged medication routine for at least 4 weeks before joining
  • People who have reliable internet access and the ability to take part in video or online health appointments
  • People who are able to understand and agree to take part in the trial on their own behalf
  • People who are willing to follow the treatment plan and attend all required follow-up appointments

Who may not be able to join:

  • People who have metal implants in their head or neck (everyday dental fillings are generally fine)
  • People who are pregnant or currently breastfeeding
  • People who have serious skin problems in the areas where electrodes (small sensors) would be placed on the body
  • People who have a history of epilepsy or seizures, unless the specific technology used is considered safe for them (confirm with trial site)
  • People who have had a stroke or serious brain injury within the last 6 months
  • People whose memory or thinking difficulties are severe enough to prevent them from understanding the treatment
  • People with certain other neurological (brain or nervous system) conditions that would make the brain stimulation treatment unsafe (confirm with trial site)
  • People who are already taking part in another clinical trial
  • People who are unable to commit to completing the full treatment programme and all follow-up visits

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
U: The Mind Company
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
1 March 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in MDS-UPDRS Part III Motor Scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov